Jumia Technologies AG - ADR vs Regeneron Pharmaceuticals Inc — how do they compare? Jumia Technologies AG - ADR trades at $5.7 (market cap $719.58M), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 114× Jumia Technologies AG - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | REGN | |
|---|---|---|
Market Cap | $719.58M | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $812.27 |
52-Week Low | $5.69 | $555.51 |
Enterprise Value | $666.68M | $76.77B |
Dividend Yield | — | 0.47% |
Trailing returns across standard periods
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →